Vascular endothelial growth factor (VEGF) levels in induced sputum and plasma in asymptomatic and COPD smokers. Correlation with airway and systemic inflammation Source: Eur Respir J 2006; 28: Suppl. 50, 652s Year: 2006
Serum levels of vascular endothelial growth factor (VEGF) are elevated in patients with acute exacerbated COPD Source: Eur Respir J 2005; 26: Suppl. 49, 350s Year: 2005
Elevated serum levels of oxidative stress biomarkers in patients with lung cancer Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010
Increased levels of vascular endothelial growth factor in induced sputum in asthmatic patients Source: Eur Respir J 2002; 20: Suppl. 38, 1s Year: 2002
Pro- and anti-inflammatory cytokines TNF-alpha, IFN-gamma, IL-10 and TGF-beta1 levels in blood serum as markers of plasmaferesis success and inflammation activity in lung sarcoidosis (LS) Source: Eur Respir J 2006; 28: Suppl. 50, 676s Year: 2006
Released mediators in ex vivo 3D-model of lung fibrosis correspond to elevated serum biomarkers in IPF Source: Virtual Congress 2021 – Genetics and translational aspects of idiopathic pulmonary fibrosis Year: 2021
PP231 – Released mediators in ex vivo 3D-model of lung fibrosis correspond to elevated serum biomarkers in IPF Source: ERS Lung Science Conference 2021 Year: 2021
Alterations in gene expression of RAGE and its sheddases in blood of COPD patients do not relate to decreased plasma (e)sRAGE levels Source: International Congress 2014 – Mechanisms of COPD and inhalation injury Year: 2014
N-acetyl cysteine inhibits IL-17-induced IL-8 production from human airway smooth muscle cells - a possible role for anti-oxidant treatment in chronic lung rejection? Source: Eur Respir J 2003; 22: Suppl. 45, 202s Year: 2003
Mechanisms of vascular endothelial cell injury in response to intermittent and continuous hypoxia exposure and protective effects of anti-inflammatory and anti-oxidant agents Source: International Congress 2019 – Novel methods, diagnostics and biomarkers in chronic lung diseases Year: 2019
Antifibrotics modulate B lymphocyte activation resulting in a decrease of the profibrotic milieu in patients with pulmonary fibrosis Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019
Late Breaking Abstract - Increased serum levels of YKL-40 in male smoking chronic obstructive pulmonary disease patients associated with altered miRNA levels in alveolar macrophages Source: Virtual Congress 2020 – New biomarkers for management of obstructive diseases Year: 2020
Increased circulating endothelial microparticles in COPD Source: Annual Congress 2013 –COPD: new markers of diseases Year: 2013
Increased CCL18 serum levels in patients with pulmonary fibrosis which reflect disease severity Source: Eur Respir J 2005; 26: Suppl. 49, 21s Year: 2005
Attenuation of bleomycin-induced pulmonary fibrosis by direct thrombin inhibition is accompanied by a reduction in connective tissue growth factor mRNA levels Source: Eur Respir J 2001; 18: Suppl. 33, 199s Year: 2001
Decreased reactivity of the alveolar macrophages in relation to ICAM-1 expression after IFNγ stimulation in lung cancer patients Source: Eur Respir J 2002; 20: Suppl. 38, 276s Year: 2002
Carbocisteine in vivo reduces circulating miR-21 and IL-8 in exacerbated COPD patients Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019
The inhibitory effect of fenretinide on the expression of inflammatory cytokines, possible molecular target of the drug and its relevance to cystic fibrosis. Source: Research Seminar 2009 - Molecular and Cellular aspects of Chronic Lung Disease Year: 2009
iNOS inhibition modulates lung tissue inflammation via oxidative stress pathway activation Source: Annual Congress 2008 - Inflammatory trigger mechanisms in asthma and COPD Year: 2008
Plasma markers of oxidative protein damage do not correlate with lung function or COPD in smokers Source: Eur Respir J 2006; 28: Suppl. 50, 144s Year: 2006